Hostname: page-component-84b7d79bbc-tsvsl Total loading time: 0 Render date: 2024-07-27T16:51:49.949Z Has data issue: false hasContentIssue false
  • English
  • Français

Graphene Oxide as a drug carrier for delivery of zoledronic acid in secondary bone cancer treatment

Published online by Cambridge University Press:  15 February 2019

Sepideh Tavakoli  and
Duygu Ege
Sepideh Tavakoli*
Affiliation:
Institute of Biomedical Engineering, Boğaziçi University, Istanbul, Turkey
Duygu Ege
Affiliation:
Institute of Biomedical Engineering, Boğaziçi University, Istanbul, Turkey
*
*(Email: sep.tavakoli@gmail.com)
Get access

Abstract

In this study, Zoledronic acid (ZOL), a type of nitrogen containing bisphosphonate, was loaded on graphene oxide (GO) particles to increase the particle size of the drug-nano-carrier complex which reduces drug filtration by the kidney and consequently, increases drug circulation time and its tumor uptake. The conjugation between ZOL and GO occurs via π− π stacking and hydrogen bonding interactions, and therefore, the drug may be gradually released from GO in physiological conditions which eliminates the need to apply high doses of the drug. Loading and release profile of ZOL on GO particles were investigated by using UV-Vis spectroscopy. Samples with different concentrations of 0.025-1.25 mg/ml of ZOL were loaded on 0.2 mg/ml GO. UV analysis showed that the maximum loading happens at ZOL to GO ratio of 1:0.2. This loading was obtained when 1 mg/ml of ZOL was initially loaded on 0.2 mg/ml of GO nanoparticles. The drug and drug carrier complexes were characterized by UV-vis spectroscopy.

Keywords

nanostructurespectroscopybiomaterial
Type
Articles
Information
MRS Advances , Volume 4 , Issue 21: Biomaterials and Soft Materials , 2019 , pp. 1231 - 1236
Copyright
Copyright © Materials Research Society 2019 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Nadar, R.A., Margiotta, N., Iafisco, M., Jeroen, D Beucken, J.V., Boerman, O.C., and Leeuwenburgh, S.C., Adv. Healthc. Mater. 6, 8 (2017).CrossRefGoogle Scholar
Michael, G., Dubsky, P., and Hadji, P., Prevention of Bone Metastases (Springer, Berlin, Heidelberg, 2012), p. 65-91.Google Scholar
Saad, F., and Lattouf, J., Prevention of Bone Metastases (Springer, Berlin, Heidelberg, 2012), p. 109-126.CrossRefGoogle ScholarPubMed
Misra, R. , Acharya, S., and Sahoo, S.K., Drug. Discov. Today 15, 19-20 (2010).CrossRefGoogle Scholar
Lin, J.H., Bone 18, 2 (1996).CrossRefGoogle ScholarPubMed
Erez, R., Ebner, S., Attali, B., and Shabat, D., Bioorganic & Med. Chem. Lett. 18, 2 (2008).CrossRefGoogle Scholar
Yang, X., Zhang, X., Liu, Z., Ma, Y., Huang, Y., and Chen, Y., Phys. Chem. C 112, 45 (2008).Google ScholarPubMed
Khajuria, D.K., Razdan, R., and Mahapatra, D.R., Eur. J. Pharm. Sci. 66, 173-183 (2015).CrossRefGoogle Scholar